What a nitrosamine drug substance-related impurity (NDSRI) is and how it differs from small-molecule nitrosamines such as NDMA and NDEA, the five potency categories and acceptable intake limits in FDA's August 2023 guidance, how ICH M7(R2) frames them, what FDA posted after the August 1, 2025 deadline, and what Atlas found when it searched the full text of 510 drug CGMP warning letters dated January 2021 to October 2026.